AMYLYX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.620 USD | +5.22% |
|
+10.55% | -82.20% |
Chart calendar Amylyx Pharmaceuticals, Inc.
c06aea2481f57233ad0ff17f263d1453.f7o9xvMNFVKQmFPosKQCW4f1qKEIQjqEeLQDfSSaJjw.Kd56t701XAGmzRiu5vFUGM_D7PNGI1K8SvA3SkD8ZWwIy0SItDRGKKnpGg~d3997e3bf8a481633569252abd4129f8
Upcoming events on Amylyx Pharmaceuticals, Inc.
Past events on Amylyx Pharmaceuticals, Inc.
| 2024-09-11 08:30 am | H.C. Wainwright Global Investment Conference |
| 2024-09-10 03:45 pm | Baird Global Healthcare Conference |
| 2024-09-05 01:50 pm | Morgan Stanley Healthcare Conference |
| 2024-08-08 08:00 am | Q2 2024 Earnings Call |
| 2024-08-08 07:00 am | Q2 2024 Earnings Release |
| 2024-07-10 08:00 am | Acquisition of Avexitide from Eiger BioPharmaceuticals by Amylyx Pharmaceuticals, Inc Call |
| 2024-06-11 08:00 am | Goldman Sachs Global Healthcare Conference |
| 2024-06-06 09:00 am | Annual General Meeting |
| 2024-05-15 11:40 am | BofA Securities Health Care Conference |
| 2024-05-09 08:00 am | Q1 2024 Earnings Call |
| 2024-05-09 07:00 am | Q1 2024 Earnings Release |
| 2024-04-16 11:15 am | American Academy of Neurology Meeting |
| 2024-04-10 01:30 pm | HELIOS Phase 2 Clinical Trial Results Call |
| 2024-03-08 08:00 am | AMX0035 Phase III Clinical Trial Results Call |
| 2024-03-04 06:00 pm | Muscular Dystrophy Association Clinical & Scientific Conference |
| 2024-02-22 08:00 am | Q4 2023 Earnings Call |
| 2024-02-22 07:00 am | Q4 2023 Earnings Release |
| 2023-12-07 12:45 pm | Motor Neurone Disease Association International Symposium - Poster No: TST-12 |
| 2023-12-07 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: CLT-11 |
| 2023-12-07 11:45 am | Motor Neurone Disease Association International Symposium - Poster No: CW-06 |
Annual results
| Fiscal Period | December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,29 0,40 -28.08% | 22,2 4,41 403.57% | 381 380 0.27% | 87,6 | 0,00 | 0,13 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 -86,7 - | -201 -212 5.05% | 39,9 53,1 -24.81% | -310 | -180 | -237 |
|
EBIT Million USD | Released Forecast Spread | -82,7 -97,2 14.95% | -201 -212 4.84% | 38,8 52,9 -26.65% | -261 | -143 | -134 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -87,9 -92,0 4.42% | 0,00 0,00 - | 54,3 69,4 -21.78% | 0,00 | 0,00 | 0,00 |
|
Net income Million USD | Released Forecast Spread | -87,9 -97,2 9.5% | -198 -207 4.16% | 49,3 63,0 -21.78% | -233 | -109 | -82,7 |
|
EPS USD | Released Forecast Spread | -13,4 -15,4 13.03% | -3,39 -3,54 4.15% | 0,70 0,90 -22.38% | -3,46 | -1,53 | -1,02 |
| Announcement Date | 30/03/22 | 13/03/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | June | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,35 0,08 314.02% | 21,9 4,72 363.26% | 71,4 59,7 19.75% | 98,2 92,1 6.6% | 103 114 -9.65% | 108 107 1.31% | 88,6 98,3 -9.87% | -1,02 8,53 -111.99% | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -54,7 -56,9 3.88% | -44,6 -53,4 16.47% | -2,05 -19,7 89.57% | 20,2 3,45 486.33% | 18,7 29,0 -35.46% | 1,93 14,6 -86.79% | -11,7 -9,05 -28.88% | -76,3 -60,2 -26.78% | -57,3 | -43,1 | -48,7 | -49,9 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 1,40 -9,80 114.32% | 24,0 6,90 247.93% | 22,4 30,6 -26.76% | 6,48 21,6 -70.01% | -119 -15,5 -664.77% | -72,7 -64,8 -12.19% | ||||||
|
Net income Million USD | Released Forecast Spread | -53,8 -56,3 4.46% | -42,7 -51,3 16.78% | 1,57 -15,1 110.43% | 22,1 2,80 687.42% | 20,9 30,0 -30.33% | 4,73 16,5 -71.3% | -119 0,60 -20065.21% | -72,7 -38,7 -87.86% | -35,9 | -37,6 | ||
|
EPS USD | Released Forecast Spread | -0,92 -0,97 4.66% | -0,65 -0,81 19.75% | 0,02 -0,22 109.09% | 0,31 -0,04 985.71% | 0,30 0,42 -29.13% | 0,07 0,23 -69.75% | -1,75 0,01 -23433.33% | -1,07 -0,70 -53.41% | -0,57 | -0,60 | ||
| Announcement Date | 10/11/22 | 13/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 22/02/24 | 09/05/24 | 08/08/24 | - | - | - | - |
More events
Past sector events for Amylyx Pharmaceuticals, Inc.
| 2024-09-09 04:05 pm | AVID BIOSERVICES, INC.: Q1 2025 Earnings Release |
| 2024-09-05 06:30 am | KALVISTA PHARMACEUTICALS, INC.: Q1 2025 Earnings Release |
| 2024-08-30 11:56 pm | SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-30 | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-29 | CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-29 | BEIJING BOHUI INNOVATION BIOTECHNOLOGY GROUP CO., LTD.: Q2 2024 Earnings Release |
| 2024-08-29 | HUALAN BIOLOGICAL VACCINE INC.: Q2 2024 Earnings Release |
| 2024-08-29 | HUALAN BIOLOGICAL ENGINEERING INC.: Q2 2024 Earnings Release |
| 2024-08-29 07:32 am | CLINUVEL PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
| 2024-08-28 | AIM VACCINE CO., LTD.: Q2 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AMLX Stock
- Calendar Amylyx Pharmaceuticals, Inc.